Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer

Abstract

BackgroundAberrated activation of cMet in gastric cancer contributes to tumor growth, angiogenesis and metastasis. cMet-overexpressing gastric cancer has a poor prognosis because of high tumor metastasis and limited therapeutic options. Luteolin is a common dietary flavonoid with antitumor properties. However, the antitumor effect of luteolin on cMet-overexpressing gastric cancer remain unclear.MethodsTwo cMet-overexpressing patient-derived human tumor xenograft (PDTX) models of gastric cancer were established, and treated with luteolin or vehicle to evaluate the antitumor effects of luteolin. Tumor specimens were subjected to H&E staining and immunohistochemistry. MKN45 and SGC7901 cells that show high cMet expression were treated with varying concentrations of luteolin and evaluated by western blot, cell viability, apoptosis, migration, and invasion assays.ResultsLuteolin inhibited the tumor growth in cMet-overexpressing PDTX models. Immunohistochemistry demonstrated that expression of cMet, MMP9 and Ki-67 were significantly down-regulated. Luteolin inhibited proliferation, promoted apoptosis and reduced the invasiveness of MKN45 and SGC7901 cells. Western blot revealed that luteolin promoted the activation of apoptosis-related proteins, caspase-3 and PARP-1, and down-regulated the invasion-associated protein, MMP9. Further studies demonstrated that luteolin decreased the expression and phosphorylation of cMet, and downstream phosphorylation of Akt and ERK. In addition, luteolin down-regulated phosphorylated Akt independently of cMet. Blocking Akt and/or ERK with the PI3K inhibitor, LY294002, or the ERK inhibitor, PD98059, induced down-regulation of MMP9 and up-regulation of cleaved caspase-3 and PARP-1, resembling the effects of luteolin.ConclusionsOur findings ,for the first time, demonstrate that luteolin exerts marked antitumor effects in cMet-overexpressing PDTX models of gastric cancer, through a mechanism likely involving cMet/Akt/ERK signaling. These findings indicate that luteolin may act as a potential therapeutic option for cMet-overexpressing gastric cancer.Electronic supplementary materialThe online version of this article (doi:10.1186/s12967-015-0398-z) contains supplementary material, which is available to authorized users.

HIF‐1α/VEGF signaling‐mediated epithelial–mesenchymal transition and angiogenesis is critically involved in anti‐metastasis effect of luteolin in melanoma cells

“…*p < 0.05 and **p < 0.01 indicate a significant difference from the control group compounds targeting EMT and angiogenesis have been the efficient therapeutic approach for the treatment of metastatic cancers . Luteolin, a flavonoid that is found in more than 300 plant species, has recently been shown to inhibit a variety of cancers, both in vitro and in vivo, with little to minimal toxicity (Lu et al, 2015;Ruan et al, 2012). Previous studies have shown that luteolin inhibits metastasis of triple-negative breast cancer cells through suppressing EMT (Cook et al, 2017).…”

Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells

“…This latter finding is in agreement with Bagli et al30 and Pratheeshkumar et al,34 who reported that low concentrations of LU (10–20 µM) acted as both a potent PI3K inhibitor and an inhibitor of metalloproteinase MMP9. Additional evidence implicates downregulation of PI3K phosphorylation and MMP9 as being responsible for the anti-invasive capacity of LU, perhaps explaining its ability to reduce the invasive potential of various cancer cell lines in vitro 38–42. Because the VEGF-induced PI3K pathway mediates cell survival, migration, and proliferation, we propose that our findings that LU inhibits TNBC cell migration support the notion that it acts via multiple mechanisms likely potentiated through blockade of PI3K phosphorylation and/or MMP-mediated VEGF signaling.…”

Luteolin Decreases Epidermal Growth Factor Receptor‐Mediated Cell Proliferation and Induces Apoptosis in Glioblastoma Cell Lines

“…Along with its antioxidant and anti‐inflammatory properties, luteolin has demonstrated anticancer effects in a variety of types of cancer through several mechanisms including inducing cell death, slowing cell proliferation and halting cell growth. Several studies have shown that luteolin down‐regulates Akt phosphorylation in gastric, breast, brain and other cancer cell lines .…”